Table 5.
Analysis of pro- and anti-inflammatory markers (MAKE365)
| Pro- and Anti-Inflammatory Markers | Patients without MAKE365, d0 | Patients with MAKE365, d0 | P Value | Patients without MAKE365, d3 | Patients with MAKE365, d3 | P Value |
|---|---|---|---|---|---|---|
| MIF, median (Q1, Q3), pg/ml | 15,019.2 (10,189.2, 44,648.4) | 18,870.6 (9500.1, 45,180.3) | 0.96 | 11,283.6 (5988.6, 23,681.1) | 95,32.2 (4881.6, 19,211.7) | 0.24 |
| IL-6, median (Q1, Q3), pg/ml | 11,51.4 (354.1, 1794.9) | 967.4 (321.8, 2102.5) | 0.60 | 282.7 (102.1, 552.1) | 253.7 (95.4, 687.4) | 0.81 |
| IL-8, median (Q1, Q3), pg/ml | 313.6 (123.5, 571.2) | 256.6 (92.5, 538.5) | 0.73 | 73.3 (30.9, 129.2) | 47.3 (25.5, 120.1) | 0.29 |
| IL-10, median (Q1, Q3), pg/ml | 44.6 (20.8, 153.0) | 47.4 (18.3, 203.8) | 0.85 | 22.2 (9.6, 48.6) | 16.8 (9.7, 52.9) | 0.91 |
| IL-18, median (Q1, Q3), pg/ml | 727.0 (343.7, 1153.7) | 575.5 (285.0, 1376.7) | 0.63 | 777.3 (350.9, 1849.6) | 539.8 (301.8, 1448.0) | 0.14 |
| TNFR-1, median (Q1, Q3), pg/ml | 1600.3 (1221.1, 2104.9) | 1788.2 (1122.2, 2521.0) | 0.50 | 1447.8 (951.1, 2021.1) | 2023.4 (1200.5, 2995.0) | <0.01 |
| TNFR-2, median (Q1, Q3), pg/ml | 22,630.0 (14,873.8, 27,055.0) | 18,901.6 (12,856.0, 28,880.0) | 0.23 | 20,880.0 (11,916.3, 29,420.0) | 24,820.0 (16,775.5, 39,677.5) | <0.04 |
d0, Blood samples were drawn at the time of randomization; d3, blood samples were drawn 72 h after randomization.